ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 057,80
-0,92%
Dow Jones
38 798,42
-0,69%
DAX
18 677,87
-0,45%
Brent Oil
83,80
1,15%
Bitcoin
67 837,23
-2,24%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Zentalis Pharmaceuticals Inc (ZNTL)

  7. Zentalis Pharmaceuticals Inc (ZNTL) Actualités

ZNTL

Zentalis Pharmaceuticals (ZNTL)

Zentalis Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ZNTL
DateHeureSourceTitreSymboleSociété
23/05/202423h01GlobeNewswire Inc.Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:ZNTLZentalis Pharmaceuticals Inc
14/05/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:ZNTLZentalis Pharmaceuticals Inc
07/05/202413h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZNTLZentalis Pharmaceuticals Inc
07/05/202413h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZNTLZentalis Pharmaceuticals Inc
07/05/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ZNTLZentalis Pharmaceuticals Inc
01/05/202423h30GlobeNewswire Inc.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
02/04/202422h05GlobeNewswire Inc.Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024NASDAQ:ZNTLZentalis Pharmaceuticals Inc
29/02/202423h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZNTLZentalis Pharmaceuticals Inc
29/02/202423h14Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ZNTLZentalis Pharmaceuticals Inc
28/02/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
27/02/202413h08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZNTLZentalis Pharmaceuticals Inc
27/02/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational UpdatesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
14/02/202401h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ZNTLZentalis Pharmaceuticals Inc
13/02/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ZNTLZentalis Pharmaceuticals Inc
13/02/202402h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
13/02/202402h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
25/01/202413h00GlobeNewswire Inc.Zentalis Pharmaceuticals Strengthens Management Team with Key AppointmentsNASDAQ:ZNTLZentalis Pharmaceuticals Inc
08/01/202413h00Business WireImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology PlatformNASDAQ:ZNTLZentalis Pharmaceuticals Inc
04/01/202402h19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
09/11/202313h00GlobeNewswire Inc.Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD CowenNASDAQ:ZNTLZentalis Pharmaceuticals Inc
06/11/202313h18GlobeNewswire Inc.Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
06/09/202313h00GlobeNewswire Inc.Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:ZNTLZentalis Pharmaceuticals Inc
09/08/202313h00GlobeNewswire Inc.Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesNASDAQ:ZNTLZentalis Pharmaceuticals Inc
01/08/202322h28GlobeNewswire Inc.Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
01/08/202313h00GlobeNewswire Inc.Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy OfficerNASDAQ:ZNTLZentalis Pharmaceuticals Inc
20/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
20/06/202322h31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
16/06/202323h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
15/06/202313h13Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:ZNTLZentalis Pharmaceuticals Inc
15/06/202312h01GlobeNewswire Inc.Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common StockNASDAQ:ZNTLZentalis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ZNTL

Dernières Valeurs Consultées

BIT
F12855
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés